Clinical Trials Browser

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Central Nervous System Neoplasms, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT02763761 2018-10-09

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

Phase 2 Withdrawn

DermatologicGenitourinaryThoracic

Carcinoma, Renal Cell, Lung Neoplasms, Melanoma

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Phase 2 Withdrawn

DermatologicGastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

NCT01328106 2017-12-12

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

Phase 2 Withdrawn

Dermatologic

Uveal Melanoma, Neoplasms

NCT01833767 2017-08-24

Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma

Phase 2 Withdrawn

Dermatologic

Melanoma

NCT02400385 2017-02-01

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

Phase 2 Withdrawn

Dermatologic

Melanoma

NCT02061007 2016-05-09

Biomarker Correlates of Hypoxia in Metastatic Melanoma

Phase 2 Withdrawn

Dermatologic

Melanoma, Skin Neoplasms

NCT01851408 2015-04-15

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Phase 2 Withdrawn

Dermatologic

Melanoma, Recurrence

NCT01933061 2014-02-04

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

Phase 2 Withdrawn

Dermatologic

Melanoma

NCT00357461 2013-05-15

Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

Phase 2 Withdrawn

Dermatologic

Melanoma

NCT00025051 2013-03-22

Celecoxib in Preventing Skin Cancer

Phase 2 Withdrawn

Dermatologic

Carcinoma, Basal Cell

NCT01416844 2013-03-07

Study of Immune Responses in Patients With Metastatic Melanoma

Phase 2 Withdrawn

Dermatologic

Melanoma

NCT01216787 2013-01-31

RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery

Phase 2 Withdrawn

Dermatologic

Melanoma

NCT00085579 2012-12-12

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Phase 2 Withdrawn

Dermatologic

Melanoma

NCT00969085 2012-09-07

Trial of Curcumin in Cutaneous T-cell Lymphoma Patients

Phase 2 Withdrawn

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00298467 2010-04-26

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

Phase 2 Withdrawn

45 enrolled

DermatologicLymphoidSarcoma

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

NCT00963664 2009-09-09

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

Phase 2 Withdrawn

250 enrolled

Dermatologic

Melanoma

Clinical Trials

EPIC

Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

SUMMIST

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

Sargramostim (GM-CSF) + PD-1

PUTNET

Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)

PROMPT

SBRT as a Vaccination for Metastatic Melanoma

CheckMate 7UA

Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

CEDUVEAL-M

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma

Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

Biomarker Correlates of Hypoxia in Metastatic Melanoma

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

Celecoxib in Preventing Skin Cancer

Study of Immune Responses in Patients With Metastatic Melanoma

RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Trial of Curcumin in Cutaneous T-cell Lymphoma Patients

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma